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Abstract
Providing women with safe and effective means of contraception is important when
assessing women’s health needs. Women with HIV can spread the disease to their baby
through vertical transmission but this may be curtailed by the use of antiretroviral therapy.
Additionally, providing women who have HIV with safe contraception options improves
women’s overall health. However, there is concern that some hormonal contraceptives may
affect the metabolism with certain antiretrovirals. A literature search was conducted using
the databases Medline, PubMed, and Global Health. Articles meeting the inclusion criteria
were then assessed. Thirteen peer-reviewed articles were identified. Several studies
indicated that there were no relevant interactions for measures of disease progression,
disease transmission and tolerability. However, some articles suggested that there were
safer means of contraception that should be made available to women on antiretroviral
therapy. Efavirenz was shown to induce adverse contraception efficacy when coadministered. Collectively, hormonal contraception is widely safe for women using
antiretroviral therapy. HIV positive women should be educated on the risks associated with
hormonal contraception as well as be provided with options that fit their reproductive
health needs.
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Introduction/ Purpose of the Study
Human Immunodeficiency Virus, commonly known as HIV, is a global epidemic,
effecting over 36.7 million worldwide (WHO 2017). HIV can affect both women and men
alike, additionally there is also risk for vertical transmission from mother to baby,
especially in developing countries (Malunguza, Hove-Musekwa, & Mukandavire, 2017).
Developing countries have limited access to perinatal and antiretroviral care, which may
explain higher rates of vertical transmission (Malunguza et al., 2017). Although there has
been a decline in death and birth rates due to HIV, many countries, such as those in subSaharan African are expecting exponential population growth within the next 30 years.
With this increase in population, more people may be affected by HIV/AIDS than ever
before. AIDS education exists in many of these countries, however, there is a lack of
attention in maternal health services (Malunguza et al., 2017). With the global burden of
HIV in these countries being the highest around the world, there is a desperate need for
increased women’s health services (WHO, 2017). Unintended pregnancies among HIVpositive women may have consequences for maternal morbidity and vertical transmission
(Patel et al., 2015). Researchers explain that the most important component of good
contraception in public health is the availability of choices (Stringer et al., 2007).
Additionally, the use of contraceptives can decrease the prevalence of maternal morbidity
and mortality (Tittle, Bull, Boffito, & Nwokolo, 2015). Women with HIV often use separate
medications to prevent disease progression (antiretroviral therapy) and disease
transmission (birth control). Almost 50% of those diagnosed with HIV use some form of
antiretroviral therapy (WHO 2017). Additionally, the WHO states that up to 77% of women
who are HIV-positive engage in ART (WHO 2017). Since the use of antiretroviral therapy is
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increasing worldwide, assessing the impact of its use with hormonal contraceptives will be
beneficial when addressing disease transmissibility of HIV-positive women on therapy
(Kourtis et al., 2017).
It is important to examine the concurrent use of hormonal contraceptives for birth
control, and antiretroviral therapy in women with HIV (Malunguza et al., 2017). There has
been some concern with the efficacy of hormonal contraceptives and antiretroviral therapy
when co-administered. Some pharmacokinetic data suggests potential interactions
between the two medications (Kourtis et al., 2017). These interactions are a key concern
for public health officials in regards to HIV, as disease transmission and progression are
key concerns. Because antiretroviral therapy and hormonal contraceptives have common
metabolic pathways, the blood levels of both hormonal contraceptives and antiretrovirals
may be affected by their concurrent use (Landolt et al., 2013). Interactions between these
drugs could potentially lead to decreased contraceptive effectiveness, therefore increasing
the change of vertical transmission. Additionally, a decrease in ART effectiveness could lead
to increased disease progression and horizontal transmission (Nanda et al., 2017).
Enhanced toxicity is also a concern when assessing the relationships between these drugs
(Landolt et al., 2013). It is important to provide women living with HIV with safe and
effective contraception to prevent unintended pregnancy and decrease the incidence of
maternal-to-child HIV-1 transmission (Day et al., 2014). Few studies examining the
relationship between hormonal contraceptives and antiretrovirals have been conducted
and studies have shown conflicting results (Landolt et al., 2013). Studies of interactions
have been limited by short follow up times, inconclusive end points, small sample sizes and
uninfected populations (Pyra et al., 2015). Since data in the field is limited, contraception
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options for HIV-positive women receiving antiretroviral therapy is also limited (Watts et
al., 2008). The primary purpose of this study is to provide a systematic review of research
articles to determine the potential effects on hormonal efficacy and disease progression
from concurrent use of hormonal contraceptives and antiretroviral therapy in HIV-positive
women.
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Literature Review
In 2015, there were over 36.7 million people living with HIV (WHO, 2016).
Additionally, sub-Saharan Africa bears the greatest global burden of HIV/AIDS, which
account for 70% of all HIV infections. Nearly 13 million women in Sub-Saharan Africa live
with AIDS (Patel et al., 2015). HIV is spread through certain bodily fluids, such as breast
milk, blood, semen, and vaginal secretions (CDC 2016). HIV targets the body’s immune
system, more specifically CD4+ cells (CDC 2016). Although there is no cure for HIV, it can
be managed with the use of Antiretroviral therapy (ART). ART was introduced in the mid1990s, and those who are infected have greater chances to live longer lives, and decrease
the odds of transmission to others. Because no cure currently exists for HIV, prevention
and decreasing the transmission of the disease is a concern among health professionals.
The proportion of HIV and AIDS cases among women continues to grow world-wide,
with women accounting for over half of HIV-infected adults (Luque et al., 2015). Over
ninety percent of the HIV positive women in sub-Saharan Africa are between 15 and 49
years of age (Day et al., 2014). Because these woman can be considered as being in child
bearing age, it is important to address the reproductive needs of women living with the
disease. Condom use is highly recommended for HIV-infected women, but this form of
contraception is not always reliable or accessible, so therefore healthcare professionals
encourage women to use additional forms of contraception (Leticee, Viard, Yamgnane,
Karmochkine, & Benachi, 2012). Additionally, the availability of contraception among HIVInfected women who desire to have it has been a key strategy in preventing pediatric AIDS,
(Stringer et al., 2007).
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Hormonal contraceptives are steroid hormones that serves as birth control (Nanda
et al., 2017). Hormonal contraceptives, most of which contain some form of progestin, a
synthetic progestogen that mimics progesterone alone or combined with estrogen, are
widely used by women all over the globe, to prevent pregnancy and/or to alleviate
hormonal imbalances (CDC 2016, Luque et al., 2015). Globally, hormonal contraceptives
are the most widely used contraception method among women (Kourtis et al., 2017).
Women in developing countries experience a high prevalence HIV (more than 95% of HIV
infections are in developing countries), and these women tend to use contraceptive
methods such as depot medroxyprogesterone (DMPA), a hormonal contraceptive (WHO
2016, Luque et al., 2015). Hormonal contraceptives are metabolized via cytochrome P450
enzyme system in the liver, especially via CYP3A4 (Kancheva Landolt et al., 2016). The
metabolism of hormonal contraceptives allows the drug to be broken down by the body
and to carry out its hormonal purpose (Landolt et al., 2013). Globally, 14% of women use
hormonal contraception (Mitchell, 2004). A study conducted by Nieves and associates
concluded that 54% of women used a form of hormonal contraception as a means of birth
control for heterosexual couples (Nieves et al., 2015).
Treatment of HIV through antiretroviral therapy usually contains a combination of
drugs, which target different stages of the HIV lifecycle (Tittle et al., 2015). Antiretroviral
therapy has been shown to both increase and decrease the efficacy of hormonal
contraception, depending on the drug it is administered with, however findings continue to
be mixed in nature (Luque et al., 2015). There are six main classes of antiretroviral drugs
(Sharma & Walmsley, 2015). The classes of antiretroviral therapy include: nucleoside
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors
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(NNRTIs), Protease Inhibitors (PI), Integrase Inhibitors (INI), Entry Inhibitors (Sharma &
Walmsley, 2015). All of these drugs target the HIV lifecycle in different ways. Usually, two
or three of these drug classes are combined to decrease the progression of HIV (Sharma &
Walmsley, 2015). Generally, most people start HIV treatment with two NRTI drugs, along
with either one NNRTI or one PI and one INI (Nanda et al., 2017). Although NRTIs and INI
are not generally inducers of the cytochrome P450 system, PIs and NNRTIs are
metabolized by enzymes found in the cytochrome P450 system (Nanda et al., 2017) and
may specifically inhibit cytochrome 3A4, however findings continue to be mixed in nature
(Atrio et al., 2015).
Some antiretrovirals (ARVs), particularly Nevirapine and Efavirenz, are
metabolically synthesized via the cytochrome P450 enzyme system (Kancheva Landolt et
al., 2016). Since some protease inhibitors can inhibit enzyme systems like CYP3A4, the
bioavailability of drugs that use the same enzyme systems, like hormonal contraceptives,
may decrease (Atrio et al., 2015). Additionally, some studies suggest that CYP3A4 activity
differs by gender, and suggest that women have 40% higher CYP3A4 activity than men
(Luque et al., 2015). With increased activity of this enzyme, which aids in breaking down
hormonal contraception in women, examining the relationship between these drugs is key,
so that women with HIV have options that meet reproductive health needs.
Efavirenz is usually a first-line treatment for HIV, followed by nevirapine, which are
both NNRTIs (Scarsi et al., 2016). Landlot and associates found that efavirenz, in contrast to
nevirapine, when co-administered with combined oral contraceptives, is associated with
unfavorable progesterone and antiretroviral levels (Landolt et al., 2013). Patel and
associates documented a similar finding; efavirenz, compared to nevirapine experienced
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higher rates of pregnancy among those using DMPA and hormonal contraceptives (Patel et
al., 2015). Both studies note that the failure of contraceptives was minimal and was no
statistically significant different than the general population.
Effects on Contraception
Hormonal contraceptives are known to thicken the mucus of the cervix, so that
sperm cannot reach the egg (Atrio et al., 2015). Suppressed ovulation is a key determinate
in judging the efficacy of hormonal contraceptives (Luque et al., 2015). Researchers did not
observe any pregnancies concluding that DMPA is a safe and tolerable amongst women
using antiretroviral therapy (Luque et al., 2015).
Pyra and associates suggest that both oral contraceptives and implants are effective
in reducing pregnancy when co-administered with antiretroviral therapy (Pyra et al.,
2015). Although researchers found that antiretroviral therapy did not significantly
diminish the effectiveness of contraception, there was a non-statistically significant
reduced effectiveness when co-administered with the antiretroviral, efavirenz (Pyra et al.,
2015). Implants (IUDs) were the most protective contraceptive method for women
engaging in ART (Pyra et al., 2015).
Atrio and associates found that women taking protease inhibitors demonstrated
thickened cervical mucus similar to those not on antiretroviral therapy (Atrio et al., 2015).
Thickened cervical mucus serves as a barrier to sperm penetration (Atrio et al., 2015). The
findings of the research suggested contraceptive (pill) efficacy in HIV positive women
taking antiretroviral therapy that includes protease inhibitors, is an appropriate method of
birth control for HIV positive women (Atrio et al., 2015).
Effects on Disease Transmission and Progression
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Stringer and associates concluded that women who used hormonal methods were
more likely to become pregnant, as compared to the IUD (Stringer et al., 2007). Also,
women who use hormonal contraception may experience disease progression more
commonly than those using the IUD (Stringer et al., 2007). Research suggests the IUD may
be a safer and more effective option than hormonal contraception in HIV+ women, in
regards to disease progression (Stringer et al., 2007). However, these results are not
consistent.
Using blood measures to assess CD4+ cell counts, Whitman and associates found
that there was no statistically significant increase in disease progression among those that
used hormonal contraception, including DMPA and the pill, as compared to those that used
non-hormonal methods such as the IUD or condoms, (Whiteman et al., 2016). Additionally,
those engaging in antiretroviral therapy saw no statistically significant difference in mean
changes of CD4+ cell counts when comparing those that used hormonal methods to those
that did not (Whiteman et al., 2016). The researchers concluded that hormonal
contraception was not significantly associated with HIV disease progression or
antiretroviral effectiveness among women with HIV (Whiteman et al., 2016).
Another study assessing DMPA’s effect on HIV antiretroviral drugs evaluated the
safety and tolerability of co-administration (Watts et al., 2008). Tolerability was measured
by the instances of adverse side effects (Watts et al., 2008). Researchers assed DMPA use
with various antiretroviral drugs including nelfinavir, efavirenz, and nevirapine (Watts et
al., 2008). Although some participants experienced adverse side effects including vaginal
bleeding, headache, abdominal pain, mood changes, and other symptoms, researchers
attributed these findings to the general side effects of DMPA that could occur in all women
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regardless of HIV status (Watts et al., 2008). The study found that there were no significant
changes in CD4+ cell count or HIV RNA levels with the use of DMPA (Watts et al., 2008).
This suggested that co-administration of hormonal contraceptives and antiretrovirals is
safe among HIV-positive women.
Use of DMPA In a similar study, researchers investigated DMPA and antiretroviral
use and compared plasma and genital HIV-1 RNA shedding (Day et al., 2014). Researchers
found that DMPA expose did not increase detection of plasma nor cervical HIV-1 RNA (Day
et al., 2014). Day and associates concluded that administration of DMPA among HIVinfected women is a safe option for those currently engaging in ART therapy.
Effects on Pharmacokinetics
Kancheva and associates suggest that there are no relevant interactions between
hormonal contraceptives and antiretrovirals. However, The researchers observed that
there was a high variability in estrogen levels of the participants (Landolt et al., 2013). This
may warrant concern, as there could potentially be an issue in estrogen breakdown among
participants. The study found no clinically relevant interactions between DMPA and the
antiretroviral drugs lopinavir and a low dose ritonavir among HIV-positive women,
compared to those that are HIV-positive, but are not receiving antiretroviral therapy. Both
lopinavir and ritonavir are both protease inhibitors (Luque et al., 2015). There was no
significant difference in hormonal levels of either contraceptive in blood samples between
the two groups.
Some research has shown that certain classes of antiretroviral therapy, such as PIs
and NNRTIs can inhibit hepatic enzymes such as cytochrome 3A4, however findings
continue to be mixed in nature (Atrio et al., 2015).
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Methods
The process of the systematic review started with the research question, “Does the
use of antiretroviral therapy or hormonal contraceptives alter the efficacy of either drug
when used concurrently in HIV-positive women?” Hormonal contraceptives in this study
include birth control pills and the DMPA shot. The systematic review search was conducted
through Georgia State University’s library website using the following databases: Global
Health, Medline, and PubMed. Based on the purpose of this study keywords such as:
hormonal contraceptives, contraception, antiretroviral therapy, disease
transmission/progression and ART were used to conduct the search. The search criteria
included: ((hormonal contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)).
After this search was conducted the search criteria was again searched using disease
transmission/progression. The search criteria included: ((hormonal contraception) OR
(contraceptive)) AND ((antiretroviral) OR (art)) AND ((disease progression) or (disease
transmission)). The results from both searches were combined as the results of the second
search were yielded in the initial search. All articles from the systematic review were
chosen from these databases. The flowchart (Figure 1) details the process of the systematic
review and how the final articles were chosen. The primary goal for the systematic review
was whether co-administration of hormonal contraceptives and antiretroviral therapy had
an effect on efficacy of either drug. The secondary goals were to assess whether coadministration played a role in disease progression and pregnancy acquisition. The
inclusion criteria for the systematic review consisted of randomized and nonrandomized
studies, including randomized control trials and cohort studies. Also, all studies included
the systematic review co-administered both antiretroviral therapy and hormonal
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contraception. The inclusion criteria are detailed in Table 1. Only articles that assessed
HIV-positive women were included. English language articles included the systematic
review were published between the following dates: January 2007-March 2017. There
were no restrictions based on age, country, or type of antiretroviral therapy used. After
eliminating articles that did not fit the inclusion criteria, remaining articles were reviewed
based on the research questions and the availability of full text articles. After assessing the
articles that met all of the inclusion criteria, the final literature for the systematic review
was chosen. Finally, a quality assessment was conducted on eligible articles based on the
following criteria: study design, purpose clearly stated, use of antiretroviral therapy, use of
hormonal birth control (pill/ DMPA) stated, conclusions appropriate per results. The
quality assessment is detailed in Table 2.
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Figure 1. Flowchart of Selection of Studies
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Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria
• Articles using both hormonal
contraceptives and antiretroviral
therapy within the study
• Cohort Studies
• Randomized/Non-randomized
Control Trials
• Female Subjects
• Full text English Articles
• Articles published between January
2007- March 2017
• Articles with primary outcomes of
efficacy, disease progression, or
pregnancy incidence (ovulation)

Exclusion Criteria
• Systematic Reviews
• Articles not in English
• Studies without full text available
after search
• Case Control Studies
• Studies including nonhuman subjects
• Secondary Analysis
• Articles with behavioral outcomes
(for the interest of this study,
behavioral outcomes were excluded
due to the initial purpose being drug
efficacy)
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Table 2. Quality Assessment of Reviewed Articles
Author

Purpose
Clearly
Stated

Use of
Antiretroviral

Atrio
(2015)

Yes

Yes

Day
(2015)
Kancheva
Landlot
(2016)
Landlot
(2013)

Yes

Yes

Yes

Yes

Yes

Yes

Luque
(2015)

Yes

Yes

Nanda
(2008)

Yes

Yes

Nanda
(2013)

Yes

Yes

Patel
(2015)
Polis
(2012)
Pyra
(2015)
Stuart
(2011)
Watts
(2008)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Whiteman
(2016)

Yes

Yes

Use of
Conclusions
Study
hormonal
Appropriate
Design
Contraception per Results
(Pill/DMPA)
Yes
Yes
NonRandomized
Clinical Trial
Yes
Yes
Prospective
Cohort Study
Yes
Yes
Nonrandomized
Clinical Trial
Yes
Yes
Nonrandomized
Clinical Trial
Yes
Yes
NonRandomized
Clinical Trial
Yes
Yes
NonRandomized
Clinical Trial
Yes
Yes
NonRandomized
Clinical Trial
Yes
Yes
Retrospective
Cohort Study
Yes
Yes
Prospective
Cohort Study
Yes
Yes
Retrospective
Cohort Study
Yes
Yes
Prospective
Cohort Study
Yes
Yes
NonRandomized
Clinical Trial
Yes
Yes
Prospective
Cohort Study
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Results
Georgia State University’s Library website provides 21 A-Z databases for student
use. The databases most appropriate for this systematic review were PubMed, Medline, and
Global Health. PubMed is maintained by the National Center for Biotechnology Information
(NCBI) at the US National Library of Medicine (NLM) and provides biomedical literature
from MEDLINE, life science journals, and online books in the fields of life sciences,
behavioral sciences, chemical sciences and bioengineering. Using the keywords ((hormonal
contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)), and ((hormonal
contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)) AND ((disease
progression) or (disease transmission)), PubMed yielded 617 citations. The articles were
filtered to show only full text articles, which yielded 506 citations. The titles of the articles
and the abstracts were reviewed for relevance, 24 articles were identified and 9 articles
met the inclusion criteria.
Global Health is a public health database that provides information in international
health, biomedical life sciences, public health nutrition, non-communicable diseases and
more. The same keyword search was used for Global Health as PubMed. Global Health
yielded 227 citations. The titles of the citations were evaluated as well as the abstracts for
relevancy. There were 21 articles reviewed and 3 met the inclusion criteria for the
systematic review.
The Medline database combines the National Library of Medicine’s database
with links to full text articles. The Medline database provides information from leading
medical journals on information relating to medicine, dentistry, the healthcare system,
preclinical sciences, and veterinary medicine. The keyword search yielded 325 citations.
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The titles of the articles were evaluated as well as abstracts for relevancy. There were 27
articles reviewed and only one met the inclusion criteria for the systematic review. Most of
the articles that met the inclusion criteria were provided on at least two of the databases. It
is also important to note that all of the articles identified for the secondary outcomes, such
as disease transmission were included in the above keyword search. All of the articles
identified in the systematic review met all inclusion criteria and the outcomes were
relevant to the study. Also, there were additional articles that could have been considered
for the systematic review, but these databases were not available through the Georgia State
University Library system.
Table 3 details the characteristics of the studies included in the systematic review.
The studies in the systematic review varied in setting, however, all of the studies were
published from 2007-2017. 6 (46%) of the studies were conducted in African countries. Of
the 13 articles that met the inclusion criteria, one study (7.7%) had outcomes that found
increased disease progression. 6 studies (46%) of the studies had outcomes that monitored
ovulation, cervical mucus, or pregnancy rates. Four studies (31%) assessed the
pharmacokinetics of co-administration of antiretroviral therapy and hormonal
contraception. One study detailed virological failure rates, (defined as failure to achieve
virologic suppression, switch to second line therapy, or death within 12 months of ART
initiation), of antiretroviral therapy (7.7%) when co-administered with hormonal
contraception. Also, there was one study that detailed HIV-1 cervical shedding.
All of the studies had a clearly stated purpose and co-administration of
antiretroviral therapy and hormonal contraception (combined oral contraceptives,
progesterone only, and/or injectable), and the conclusions were appropriate per the
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results. Additionally, 11 of the studies reported a statistical significance of the results
(Table 4), while two study reported pharmacokinetic results in graphic form. Of the 13
studies reviewed, 10 studies found no relevant interactions between co-administration of
the drugs. Whitman and Associates conducted a study detailing disease transmission found
no relevant interactions between co-administration (Whiteman et al., 2016). However, Day
and associates found an increased risk of diseases transmission among women receiving
DMPA and antiretroviral therapy (Day et al., 2014).
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Table 3. Characteristics of Studies Included in the Systematic Review
Author

Title

Study
Design

(Atrio et
al.,
2015)

The effect
of
protease
inhibitors
on the
cervical
mucus of
HIVpositive
women
taking
norethind
rone
contracep
tion
A
Prospecti
ve Cohort
Study of
the Effect
of Depot
Medroxyp
rogestero
ne
Acetate
on
Detection
of Plasma
and
Cervical
HIV-1 in
Women
Initiating
and
Continuin
g
Antiretro
viral
Therapy:

NonRandomi
zed
Clinical
Trial

(Day et
al.,
2014)

Prospect
ive
Cohort
Study

Sample
Populatio
n&
Setting
43 HIV+
women
18-44/
California

102 HIV
positive
women in
Kenya
under ART

Intervention

Outcome

16 women were
given protease
inhibitors (ART)
and
Norethindrone(pro
gesterone only
pills),
17 women were
controls, given only
Norethindrone pills

No difference in
cervical mucus score
between HIV+
women taking PI
and those not taking
PI

Women on ART
therapy were
administered
DMPA or received
no DMPA

Results suggest that
DMPA is unlikely to
increase infectivity in
HIV-positive women
who are adherent to
effective ART
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(Kanche
va
Landolt
et al.,
2016)

High
variability
of
hormonal
levels and
no
clinically
relevant
interactio
n
between
ethinyl
estradiol,
desogestr
el and
lopinavir/
ritonavir
in a small
sample of
HIVpositive
adolescen
ts:
(Landolt Efavirenz,
et al.,
in
2013)
Contrast
to
Nevirapin
e, is
Associate
d With
Unfavora
ble
Progester
one and
Antiretro
viral
Levels
When
Coadmini
stered
With
Combined
Oral
Contracep

Nonrandomi
zed
Clinical
Trial

18 HIV+
women in
Bangkok
and
Thailand

All women were
administered
ethinyl
estradiol/desogestr
el (combined oral
contraceptives)
and
Lopinavir/ritonavir
(ART)

No clinically
relevant interaction
between combined
oral contraceptives
and antiretroviral
therapy

Nonrandomi
zed
Clinical
Trial

34 Thai
HIV+
women

16 women were
administered
Efavirenz and
desogestrel/ethinyl
estradiol
(Combined Oral
Contraceptives), 18
women were
administered
Nevirapine and
desogestrel/ethinyl
estradiol

Coadministration of
Efavirenz and COCs
is associated with
unfavorable
progesterone and
antiretroviral levels
compared to
Nevirapine.
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(Luque
et al.,
2015)

(Nanda
et al.,
2008)

tives:
Depot
Medroxyp
rogestero
ne
Acetate in
Combinat
ion with a
TwiceDaily
Lopinavir
RitonavirBased
Regimen
in HIVInfected
Women
Showed
Effective
Contracep
tion and a
Lack of
Clinically
Significan
t
Interactio
ns, with
Good
Safety
and
Tolerabili
ty:
Results of
the ACTG
5283
Study
Pharmaco
kinetic
interactio
ns
between
depot
medroxyp
rogestero

NonRandomi
zed
Clinical
Trial

48 HIV+
women
from 5
AIDS
Clinical
Trial
Group
clinical
research
sites
(CRSs) and
8 National
Institute of
Child
Health and
Human
Developm
ent
(NICHD)funded
IMPAACT
CRSs

The intervention
group received
DMPA and
lopinavir/ritonavir,
the control group
received DMPA
while no
antiretroviral
therapy.

No changes in
lopinavir and
ritonavir levels after
DMPA initiation.
DMPA was well
tolerated and there
was a suppression of
ovulation.

NonRandomi
zed
Clinical
Trial

30 HIV+
women

15 using ART (
Efavirenz,
zidovudine,
lamivudine)
receiving DMPA
shots, and 15 non
ART therapy users
receiving DMPA

Pharmacokinetic
interactions were
similar in those
engaging in ART and
those who did not
receive ART therapy.
Suggesting no
interference with
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(Nanda
et al.,
2013)

(Patel et
al.,
2015)

(Polis et
al.,
2012)

ne acetate
and
combinati
on
antiretrov
iral
therapy
Nevirapin
e-based
antiretrov
iral
therapy
does not
reduce
oral
contracep
tive
effectiven
ess:
Pregnanc
y rates in
HIVpositive
women
using
contracep
tives and
efavirenzbased or
nevirapin
e-based
antiretrov
iral
therapy in
Kenya: a
retrospec
tive
cohort
study
Effect of
injectable
contracep
tive use

shots

contraceptive
effectiveness.

NonRandomi
zed
Clinical
Trial

302
women in
South
Africa and
Uganda

196 women
received
Nevirapine (ART)
and Combined Oral
Contraceptives,
206 women
received Combined
Oral Contraceptives
and no ART

Use of ART did not
affect the risk of
pregnancy or
ovulation,
suggesting
Nevirapine-based
ART does not effect
combined oral
contraceptive
effectiveness.

Retrospe
ctive
Cohort
Study

24,560
HIV
positive
women
enrolled in
HIV health
facilities in
western
Kenya

For birth control,
women used either:
DMPA, Combined
Oral Contraceptives
or Implants

Implant use was the
most protective
against pregnancy,
regardless of ART
use.

For ART regimens,
women used either:
Nevirapine-based
ART, Efavirenzbased ART
lopinavir/ritonavir
based ART or no
ART

Those using
hormonal
contraceptives
(DMPA and COCs)
saw higher
incidences of
pregnancy than
those using
implants.
Those taking
Efavirenz-based
ART therapy saw the
highest incidence of
pregnancy.

Prospect
ive
Cohort
Study

418 HIVpositive
Ugandan
Women

ART and hormonal
contraceptive use
(DMPA) levels
were use measured

Virologic failure
rates while
administered with
DMPA at 12 months
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on
response
to
antiretrov
iral
therapy
among
women in
Rakai,
Uganda

(Pyra et
al.,
2015)

(Stuart
et al.,
2011)

Effectiven
ess of
hormonal
contracep
tion in
HIVinfected
women
using
antiretrov
iral
therapy:
Combined
Oral
Contracep
tives and
Antiretro
viral
PK/PD in
Malawian
Women:
Pharmaco
kinetics
and
Pharmaco
dynamics
of a
Combined
Oral

at baseline and 12
months after the
start of the study
among women who
used both drugs

were similar to
those virologic
failure rates at
baseline.
No deleterious effect
of DMPA use on
response to ART
Injectable
contraception was
not associated with
an increased risk of
ART failure

Retrospe
ctive
Cohort
Study

5153 HIVpositive
women
followed
in HIV
prevention
studies in
Africa

Women using ART
used a variety of
ART
regimens(Nevirapi
ne and Efavirenz
were the most
common) and used
the following types
of birth control:
COCs, Injectables,
Implants, None

Hormonal
contraceptives are
highly effective in
reducing pregnancy
risk in HIV-positive
women currently
using ART

Prospect
ive
Cohort
Study

9 Malawi
Women
who were
HIV+ and
taking
ART, HIV+
women
not taking
ART and
HIV
negative
women

All women, among
the three groups
were given
hormonal
contraceptives

Combined oral
contraceptives
maintained
effectiveness
regardless of ART
use.
Hormonal levels
were higher in HIVpositive women
than in HIV-negative
women, which
debunk the notion
that COCs are less
effective when coadministered with
ART like
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(Watts
et al.,
2008)

(White
man et
al.,
2016)

Contracep
tive and a
Generic
Combined
Formulati
on
Antiretro
viral in
Malawi:
Safety
and
tolerabilit
y of depot
medroxyp
rogestero
ne acetate
among
HIVinfected
women
on
antiretrov
iral
therapy:
ACTG
A5093
Associatio
ns of
hormonal
contracep
tive use
with
measures
of HIV
disease
progressi
on and
antiretrov
iral
therapy
effectiven
ess

(Nevirapine).

NonRandomi
zed
Clinical
Trial

Prospect
ive
Cohort
Study

56 HIVpositive
women
16 HIVnegative
women

709 HIVpositive
women in
Russia

HIV-infected
women on selected
ARV regimens or
no ARV were
administered
DMPA 150 mg
intramuscularly
and evaluated for
12 weeks for
adverse events,
changes in CD4+
count and HIV RNA
levels, and
ovulation.

DMPA
administration in
HIV-infected women
on ART regimens is
similar to
observations in HIVnegative women.

Women either used
ART or No ART
Therapy while
assigned to the
following
contraception
methods: COCs,
DMPA, Nonhormonal methods

No significant
association between
use of hormonal
contraception and
disease
transmission or ART
effectiveness among
HIV-positive women

DMPA prevented
ovulation and did
not affect CD4+
counts or HIV RNA
levels
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Table 4. Detailed Results of Reviewed Articles
Author
(Atrio et
al.,
2015)

(Day et
al.,
2014)

(Kanche
va

Title
The effect
of
protease
inhibitors
on the
cervical
mucus of
HIVpositive
women
taking
norethind
rone
contracep
tion
A
Prospecti
ve Cohort
Study of
the Effect
of Depot
Medroxyp
rogestero
ne
Acetate
on
Detection
of Plasma
and
Cervical
HIV-1 in
Women
Initiating
and
Continuin
g
Antiretro
viral
Therapy:
High
variability

Intervention
Women in the
intervention group were
given protease inhibitor
regimens, while the
control group received
no ART treatment.
Women were
administered
norethindrone 0.35 mg
contraception for 21
days.

The standard ART
regimen was: zidovudine
or stavudine,
lamivudine, and
nevirapine

Statistical Results
Baseline Cervical Mucus Score (CMS) was
similar to baseline (p>.01)
CMS score after 21 days among those taking PI=
3.5
CMS score after 21 days among the control=4
(P-value> 0.28)

Compared to visits with no hormonal
contraception exposure, DMPA exposure did not
increase detection of plasma (adjusted odds
ratio (AOR) 0.81, 95% CI 0.47–1.39) or cervical
HIV-1 RNA (AOR 1.41, 95% CI 0.54–3.67)

Exposure to hormonal
contraception was
defined as reported use
within the past 70 days.
The comparison group
was women not using
hormonal contraception,
which included no
contraception, condoms
only, hysterectomy or
tubal ligation.

HIV-positive females on
Lopinavir/ritonavir-

Geometric mean ratios (GMR) of Ctrough (LPV/r
concentration) in HIV-positive women on LPV/r
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Landolt
et al.,
2016)

of
hormonal
levels and
no
clinically
relevant
interactio
n
between
ethinyl
estradiol,
desogestr
el and
lopinavir/
ritonavir
in a small
sample of
HIVpositive
adolescen
ts:

based regimen (LPV/r)
were administered COC
tablets, containing 0.030
mg ethinyl
estradiol/0.150 mg
desogestrel for 2
consecutive cycles,
starting between the
first and the third day of
the cycle. (56 study days:
21 days hormonal
tablets—7 days,
repeated)

(Landolt Efavirenz,
et al.,
in
2013)
Contrast
to
Nevirapin
e, is
Associate
d With
Unfavora
ble
Progester
one and
Antiretro
viral
Levels
When
Coadmini

Oral contraceptive (COC)
containing 0.150 mg
desogestrel /0.030 mg
ethinyl estradiol with
either nevirapine (NVP)
or efavirenz (EFV) were
administered to 34 HIVpositive women.

with COC versus HIV-negative controls with COC
only were 0.68 (95% CI: 0.42 to 1.08) or 32%
decreased (P = 0.10) for EE2; and 1.08 (95% CI:
0.73 to 1.60) or 8% increased (P = 0.68) for ENG
(active metabolite in desogestrel).
Ctrough of LPV decreased statistically
insignificantly with COC and remained above the
desired therapeutic minimum of 1.0 mg/L in all.

HIV negative controls
were administered the
COC tablets, containing
0.030 mg ethinyl
estradiol/0.150 mg
desogestrel for 2
consecutive cycles,
starting between the
first and the third day of
the cycle. (56 study days:
21 days hormonal
tablets—7 days,
repeated)

The targeted level for
contraceptive
effectiveness was
endogenous
progesterone level < 3.0
ng/mL.

All subjects (18) in the NVP group had serum
progesterone <1.0 ng/mL. Four of 16 subjects in
the EFV group had serum progesterone >1.0
ng/mL, including 3 subjects with >3.0 ng/mL
(may indicate ovulation).
The difference in progesterone levels between
the 2 groups was statistically significant (P =
0.04).
The median C12 (concentration 12 hours after
administration) of NVP increased insignificantly
with COC. The median C12 of EFV decreased
significantly (P = 0.02) by 22%. 3 of 16 subjects
(19%) in the EFV group, C12 of EFV was below
1.0 mg/L.

The targeted levels for
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(Luque
et al.,
2015)

(Nanda
et al.,
2008)

stered
With
Combined
Oral
Contracep
tives:
Depot
Medroxyp
rogestero
ne
Acetate in
Combinat
ion with a
TwiceDaily
Lopinavir
RitonavirBased
Regimen
in HIVInfected
Women
Showed
Effective
Contracep
tion and a
Lack of
Clinically
Significan
t
Interactio
ns, with
Good
Safety
and
Tolerabili
ty:
Results of
the ACTG
5283
Study
Pharmaco
kinetic
interactio

antiretroviral therapy
were >3.1 mg/L for NVP
and 1.0-4.0 mg/L for
EFV.
24 HIV positive women
receiving (10 Receiving
Lopinavir
(LPV)/Ritonavir (RTV)
based therapy, 14
receiving no therapy)

There were no changes in LPV or RTV exposure
after DMPA. DMPA was well tolerated, and
suppression of ovulation was maintained.

All women received
DMPA

15 HIV-positive women
in the control group (not
on ART) received a

N/A
The mean blood levels (area under curve) for
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(Nanda
et al.,
2013)

(Patel et
al.,
2015)

(Polis et

ns
between
depot
medroxyp
rogestero
ne acetate
and
combinati
on
antiretrov
iral
therapy
Nevirapin
e-based
antiretrov
iral
therapy
does not
reduce
oral
contracep
tive
effectiven
ess:
Pregnanc
y rates in
HIVpositive
women
using
contracep
tives and
efavirenzbased or
nevirapin
e-based
antiretrov
iral
therapy in
Kenya: a
retrospec
tive
cohort
study
Effect of

single muscular injection the first 12 weeks after DMPA administration
of DMPA 150 mg.
was 101.9 (30.2) in the ART group and 99.1
(21.6) in the non-ART group, with a ratio of 1.01
15 HIV-positive women
(95% CI 0.85–1.20).
receiving ART received a
single muscular injection Mean Cmax (maximum concentration) was 2.6 for
of DMPA 150 mg.
the intervention group and 2.5 for the control
group (ratio 1.01, 95% CI 0.84–1.22).

196 women taking
nevirapine-containing
ART treated with
combined oral
contraceptives
206 HIV- positive
women not yet eligible
for ART as a control
group treated with
combined oral
contraceptives.
Women were
administered Nevirapine
or Efavirenz based ART,
with co-administration
of implants, DMPA or
combined oral
contraceptives.

In the ART group, 43 of 168 (26%) ovulated in
cycle 1, 30 of 163 (18%) in cycle 2, and 18 of
163 (11%) in both cycles. In the control group,
26 of 168 (16%) ovulated in cycle 1, 31 of 165
(19%) in cycle 2, and 20 of 165 (12%) in both
cycles. Unadjusted odds ratio 1.36 (95%
confidence interval 0.85-2.18).
Pregnancy rates 10.0 per 100-women-years in
the ART group and 10.1 per 100-women-years
in the non-ART group (no statistical
significance).
For women using implants, adjusted pregnancy
incidence was 1.1 per 100 person-years (95% CI
0.72-1.5) for nevirapine-based ART users and
3.3 per 100 person-years (1.8-4.8) for efavirenzbased ART users (adjusted incidence rate ratio
[IRR] 3.0, 95% CI 1.3-4.6).
Women using depot medroxyprogesterone
acetate (DMPA) experienced adjusted pregnancy
incidence was 4.5 per 100 person-years (95% CI
3.7-5.2) for nevirapine-based ART users and 5.4
per 100 person-years (4.0-6.8) for efavirenzbased ART users (adjusted IRR 1.2, 95% CI 0.911.5).

418 female Ugandan

Women using combined oral contraceptive
methods had 3.1-4.1 higher rates of pregnancy
than did those using implants, with 1.6-2.8
higher rates in women using efavirenz-based
ART
Composite virologic failure rates 12 months
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al.,
2012)

(Pyra et
al.,
2015)

injectable
contracep
tive use
on
response
to
antiretrov
iral
therapy
among
women in
Rakai,
Uganda
Effectiven
ess of
hormonal
contracep
tion in
HIVinfected
women
using
antiretrov
iral
therapy:

ART initiators to
examine the effect of
injectable contraceptive

after initiation were similar to women not using
injectable contraceptives at ART initiation (11%
vs. 12%, p=0.99).

5153 HIV-infected
women followed
prospectively to
compare incident
pregnancy rates by
contraceptive method
(implant, injectable, oral
or none) and ART use.

Women not using any contraception: pregnancy
incidence rates were 13.2 and 22.5 per 100
women-years for those on and not on ART,
respectively.

aHR= adjusted hazard
ratio

Women using implants: [aHR 0.06, 95%
confidence interval (95% CI) 0.01-0.45] and not
on ART (aHR 0.05, 95% CI 0.02-0.11).
Pregnancy incidence rate was Less than 1.5 per
100 person-years among those both on and not
on ART versus 1.4 for those not using ART.
Women using Injectable (aHR 0.18 on ART and
aHR 0.20 not on ART). Pregnancy incidence rate
was 3.3 per 100 person-years among those both
on and not on ART versus 5.3 for those not using
ART.
Women using oral contraceptives (aHR 0.37 on
ART and aHR 0.36 not on ART) also reduced
pregnancy risk, though by lesser degrees.
Pregnancy incidence rates were 6.2 per 100
person-years among those both on and not on
ART versus 11.1 for those not using ART.

(Stuart
et al.,
2011)

Combined
Oral
Contracep
tives and
Antiretro

Nine women enrolled, 3
in each group.

N/A

The women in group 1
(HIV positive on ARVs)
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(Watts
et al.,
2008)

(White
man et
al.,
2016)

viral
PK/PD in
Malawian
Women:
Pharmaco
kinetics
and
Pharmaco
dynamics
of a
Combined
Oral
Contracep
tive and a
Generic
Combined
Formulati
on
Antiretro
viral in
Malawi:
Safety
and
tolerabilit
y of depot
medroxyp
rogestero
ne acetate
among
HIVinfected
women
on
antiretrov
iral
therapy:
ACTG
A5093
Associatio
ns of
hormonal
contracep
tive use
with
measures

had been on ARVs for
121 days before starting
COCs.
The women in group 2
had HIV, but did not use
ARVs.
The women in Group 3
were HIV negative
women.
Measures were reported in
Graphic form.

HIV-positive women on
ART or no ART were
administered DMPA 150
mg intramuscularly and
evaluated for 12 weeks
for adverse events,
changes in CD4+ count
and HIV RNA levels, and
ovulation

HIV-positive female
participants were
administered: combined
oral contraceptives
(COCs), depotmedroxyprogesterone
acetate (DMPA), a

Current use of COCs [adjusted hazard ratio
(aHR) 0.91, 95% confidence interval (CI) 0.56–
1.48] nor DMPA (aHR 1.28, 95% CI 0.71–2.31)
was associated with a statistically significant
increase risk for disease progression.
Among participants using ART at enrollment
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of HIV
disease
progressi
on and
antiretrov
iral
therapy
effectiven
ess

copper intrauterine
device (IUD) or
condoms.
Among participants not
using ART at enrollment,
multivariate Cox
regression was used to
assess the association
between current
contraceptive use and
disease progression
(CD4 decline to <350
cells/mm3, ART
initiation or death).

(n=77), we found no statistically significant
differences in the predicted mean changes in
CD4 cell count comparing current use of COCs
(p=.1) or DMPA (p=.3) with nonhormonal
methods.
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Discussion
Ten of the articles in the systematic review showed no relevant associations
between the use of both hormonal contraception and antiretroviral therapy among HIVpositive women. However, two of the articles showed differences in hormonal blood levels
or pregnancy risk. The purpose of this study was to address the research question ““Does
the use of antiretroviral therapy or hormonal contraceptives alter the efficacy of either
drug when used concurrently in HIV-positive women?” The secondary research question
addressed disease progression with co-administration. While some studies assessed the
effectiveness of specific antiretrovirals, such as Efavirenz or Nevirapine, which are both
NNRTIs, most of the studies used a combination method of antiretrovirals, which is most
commonly practiced among HIV-positive women.
Efavirenz, a NNRTI, was associated with higher progesterone levels in a study
conducted by Landolt and associates (Landolt et al., 2013). Efavirenz based ART is the firstline therapy recommended by the WHO in resource limiting countries (Patel et al., 2015).
Those using Efavirenz and combined oral contraceptives experienced higher progesterone
levels compared using other forms of birth control. These higher progesterone levels may
indicate ovulation and further confirm the notion that co-administration alters the efficacy
of either drug. This finding may also indicate less uptake of hormonal contraception.
Additionally, some women experienced higher pregnancy rates while receiving coadministration of antiretrovirals and DMPA, compared to other forms of contraception
such as the IUD (Patel et al., 2015). It is important to note that the results of this study may
not be due to the use of Efavirenz. The results may be a reflection of the real world efficacy
of hormonal contraceptives versus other birth control methods such as implants, as
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implants are among the most effective contraception methods available today (Patel et al.,
2015). Among the general population, DMPA and combined oral contraceptives are more
user dependent than implants, which may explain the effectiveness of the drugs (Patel et
al., 2015). The results of these studies show that the IUD may be a safer option for women
looking to avoid ovulation and minimize disease progression.
The studies addressing disease transmission showed that co-administration of the
do not increase the risk of disease transmission. No significant changes in HIV RNA or CD4+
cell counts were observed in women receiving hormonal contraception versus women not
receiving hormonal contraception (Watts et al., 2008). This was observed with both DMPA
and pill users. Additionally, Day and associates detailed HIV-1 RNA shedding in HIV
positive women engaging in ART and hormonal contraceptive practices versus those not
receiving hormonal contraception (Day et al., 2014). Researchers found that those using
hormonal contraception (DMPA) did not experience increased cervical and plasma HIV-1
RNA shedding. These findings indicate DMPA is unlikely to increase infectivity in HIVpositive women who use antiretroviral therapy (Day et al., 2014). In regards to a woman’s
own health, hormonal contraception seems to be well tolerated among antiretroviral users.
Additionally, concurrent use does not seem to increase the risk of infectivity.
This systematic review had limitations in that there is limited data on the potential
interactions of antiretroviral and hormonal contraception. The study only used databases
made available by Georgia State University, which limited the search of articles that met the
inclusion criteria. Additional databases were not used in this systematic review because
these databases required payment to garner access. Also, in some of the studies, the sample
sizes were relatively small. Therefore, without additional studies in the subject area, it may
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be problematic to generalize the results of the studies to similar populations. Also, there
were additional studies that assessed birth control in HIV-positive women, but these
studies did not co-administer antiretrovirals and hormonal contraception.
Conclusion
It is important to for HIV-positive women to have safe and effective means of
contraception. Because the proportion of AIDS cases continues to rise globally among
women, vertical transmission is a topic of concern, especially among women in
childbearing age (Watts et al., 2008). Women should also be provided options for birth
control as some women may not want children, have health problems that will make
pregnancy risky, or want to be engaged in their own family planning.
Although there are concerns about the metabolism of hormonal contraception and
antiretroviral therapy along the cytochrome P450 pathway, published data has shown
minimal interactions when the drugs are co-administered. Further research needs to be
conducted in order to evaluate the efficacy of co-administration of hormonal contraception
and HIV. Because data is currently limited on the potential interactions among hormonal
contraception and antiretroviral therapy, options for safe and effective contraceptive
options are also limited among HIV-positive women. The understanding and use of
antiretroviral therapy has grown significantly over the past 30 years and co-administration
with hormonal contraception should be further examined because it is important for HIVpositive women to have control over their health and fertility. Certain antiretroviral drugs
such as Efavirenz has shown to have negative effects on the body when co-administered
with hormonal contraception. This may indicate that more research should be done on
specific NNRTIs and PIs as it relates to concurrent use. The results of this systematic
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review indicate that women can use hormonal contraception and antiretroviral therapy
concurrently without concerns about disease transmission and disease progression.
However, there may be a warrant for concern in regards to pregnancy risk and women
should use more effective forms of contraception such as the IUD. Additionally, women
using NNRTIs or PIs should be advised of the risks associated with concurrent use, and are
provided with other options as needed.
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